Related Experiment Videos
Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic
1National Institute of Haematology, Blood Transfusion and Immunology, Budapest, Hungary.
Insights
Low classical pathway (CP) activity in chronic lymphocytic leukemia (CLL) patients is linked to shorter survival. Complement measurements may offer clinical value for predicting CLL patient outcomes.
Area of Science:
- Immunology
- Hematology
- Clinical Medicine
Background:
- The complement system, comprising classical (CP) and alternative (AP) pathways, plays a role in immune responses.
- Chronic lymphocytic leukemia (CLL) is a B-cell malignancy where complement system dysregulation may occur.
Purpose of the Study:
- To investigate the correlation between complement pathway activities and clinical course in patients with chronic lymphocytic leukemia (CLL).
- To determine if complement component levels can serve as prognostic markers for CLL patient survival.
Main Methods:
- Measured classical (CP) and alternative (AP) complement pathway activities, complement components, and circulating immune complexes in 43 CLL patients.
- Followed patient clinical course for up to 12 years, correlating initial complement values with survival duration.
- Compared complement levels between short-term and long-term survivors, and analyzed prognostic value in different disease stages (Rai stages).
Main Results:
- Depressed CP activities were frequently observed in CLL patients.
- A strong positive correlation was found between initial CP values and patient survival length (P < 0.01).
- Patients with low initial CP values had significantly shorter survival times, particularly those in Rai stages 2 and 3.
Conclusions:
- Low classical pathway (CP) activity is a significant predictor of shorter survival in chronic lymphocytic leukemia (CLL) patients.
- Complement measurements, especially CP activity, hold clinical value for assessing prognosis and guiding patient management in CLL.
- Further research into complement system modulation in CLL could offer therapeutic insights.
Abstract:
The activities of the classical (CP) and alternative (AP) complement pathways as well as the levels of some complement components and circulating immune complexes were measured in 43 patients with chronic lymphocytic leukaemia (CLL) between 1980 and 1984. Depressed CP activities were frequently found in these patients. Clinical course of the disease in the patients was followed until 1992, and compared with the initial complement values. During the follow-up period 36 patients died, death of 33 patients being related to the underlying disease. A strong positive correlation (P < 0.01) was found between the length of survival of the patients and the initial CP values. Patients were divided into two groups: group A, short-term survivors, i.e patients who died in CLL-related complications within 3 years after the complement measurements; and group B, long-term survivors who died > or = 4 years after the complement measurements due to any cause, or were alive at the end of the follow-up period. Average CP values in Group B were almost twice those in group A (P = 0.002), and a similar but less pronounced difference was found in C3 levels (P = 0.055). These differences were even more marked (P = 0.0006 and P = 0.0015, respectively) when only patients in Rai stage 2 and 3 were considered. Low classical pathway activities predicted short survival time: according to the logrank test, patients in Rai stage 2-3 with low (< mean - 2s.d. of the normal values), and normal CP levels survived for 2.0 +/- 1.1, and 4.6 +/- 3.0 years, respectively. All the nine and 11/13 patients with low CP and C4 levels, respectively, died within 3 years after the complement measurements were made. These findings indicate that complement measurements performed in CLL patients have a clinical value.